Abo Bibliothek: Guest
Journal of Environmental Pathology, Toxicology and Oncology

Erscheint 4 Ausgaben pro Jahr

ISSN Druckformat: 0731-8898

ISSN Online: 2162-6537

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.4 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.8 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.5 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00049 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.59 SJR: 0.429 SNIP: 0.507 CiteScore™:: 3.9 H-Index: 49

Indexed in

miR-125b-5p Suppresses Leukemia Cell Proliferation by Regulating MCL1

Volumen 42, Ausgabe 1, 2023, pp. 17-26
DOI: 10.1615/JEnvironPatholToxicolOncol.2022041924
Get accessGet access

ABSTRAKT

Leukemia threatens children's health, and leukemia cell proliferation and apoptosis participate in the regulation of leukemia. The current study aims to probe into the miR-125b-5p biological function in regulating leukemia cell proliferation and apoptosis by myeloid cell leukemia 1 (MCL1). Quantitative real-time polymerase chain reaction was conducted to quantify miR-125b-5p expression in leukemia cells. Cell transfection, cell-counting assay 8, Western blot, and flow cytometry assays were applied to assess the miR-125b-5p function in leukemia. A dual-luciferase reporter gene assay was applied to investigate the mechanism. miR-125b-5p was lessened in leukemia cells, and the increased miR-125b-5p repressed leukemia cell proliferation and boosted apoptosis. Further, miR-125b-5p could bound with the MCL1 3'-untranslated region and regulated its expression. Furthermore, the elevated expression of miR-125b-5p repressed leukemia cell proliferation and boosted apoptosis through downregulating MCL1. miR-125b-5p inhibited leukemia cell proliferation and boosted apoptosis through decreasing MCL1.

REFERENZEN
  1. Conneely SE, Stevens AM. Acute myeloid leukemia in children: Emerging paradigms in genetics and new approaches to therapy. Curr Oncol Rep. 2021;23(2):16.

  2. Rubnitz JE, Kaspers GJL. How I treat pediatric acute myeloid leukemia. Blood. 2021;138(12):1009-18.

  3. Brayley J, Stanton LK, Jenner L, Paul SP. Recognition and management of leukaemia in children. Br J Nursing. 2019;28(15):985-92.

  4. Jin MW, Xu SM, An Q, Wang P. A review of risk factors for childhood leukemia. Eur Rev Med Pharmacol Sci. 2016;20(18):3760-4.

  5. Tsai YH, Lin JJ, Ma YS, Peng SF, Huang AC, Huang YP, Fan MJ, Lien JC, Chung JG. Fisetin inhibits cell proliferation through the induction of G(0)/G(1) phase arrest and caspase-3-mediated apoptosis in mouse leukemia cells. Am J Chin Med. 2019;47(4):841-63.

  6. Lv G, Wang Y, Ji C, Shi C, Li Y. SPRY1 promotes cell proliferation and inhibits apoptosis by activating Hedgehog pathway in acute myeloid leukemia. Hematology. 2022;27(1):1-10.

  7. Gebarowska K, Mroczek A, Kowalczyk JR, Lejman M. MicroRNA as a prognostic and diagnostic marker in T-cell acute lymphoblastic leukemia. Int J Mol Sci. 2021;22(10):5317.

  8. Zhang S, Zhang Q, Shi G, Yin J. miR-182-5p regulates BCL2L12 and BCL2 expression in acute myeloid leukemia as a potential therapeutic target. Biomed Pharmacother. 2018;97:1189-94.

  9. Wang X, Zuo D, Yuan Y, Yang X, Hong Z, Zhang R. MicroRNA-183 promotes cell proliferation via regulating programmed cell death 6 in pediatric acute myeloid leukemia. J Cancer Res Clin Oncol. 2017;143(1):169-80.

  10. Chen H, Boutros PC. VennDiagram: A package for the generation of highly-customizable Venn and Euler diagrams in R. BMC Bioinformatics. 2011;12:35.

  11. Fayed D, Donia T, El-Shanshory M, Ali EMM, Mohamed TM. Evaluation of MicroRNA92, MicroRNA638 in acute lymphoblastic leukemia of Egyptian children. Asian Pac J Cancer Prev. 2021;22(5):1567-72.

  12. Wang D, Xin L, Lin JH, Liao Z, Ji JT, Du TT, Jiang F, Li ZS, Hu LH. Identifying miRNA-mRNA regulation network of chronic pancreatitis based on the significant functional expression. Medicine. 2017;96(21):e6668.

  13. Paul S. Integration of miRNA and mRNA expression data for understanding etiology of gynecologic cancers. Methods Mol Biol. 2019;1912:323-38.

  14. Yin Z, Shen H, Gu CM, Zhang MQ, Liu Z, Huang J, Zhu Y, Zhong Q, Huang Y, Wu F, Ou R, Zhang Q, Liu S. miR-NA-142-3P and FUS can be sponged by long noncoding RNA DUBR to promote cell proliferation in acute myeloid leukemia. Front Mol Biosci. 2021;8:754936.

  15. Boldrin E, Gaffo E, Niedermayer A, Boer JM, Zimmermann M, Weichenhan D, Claus R, Munch V, Sun Q, Enzenmuller S, Seyfried F, Demir S, Zinngrebe J, Cario G, Schrappe M, Den Boer ML, Plass C, Debatin KM, Te Kronnie G, Bortoluzzi S, Meyer LH. MicroRNA-497/195 is tumor suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia. Blood. 2021;138(20):1953-65.

  16. Liu Z, Sun J, Liu B, Zhao M, Xing E, Dang C. miRNA-222 promotes liver cancer cell proliferation, migration and invasion and inhibits apoptosis by targeting BBC3. Int J Mol Med. 2018;42(1):141-8.

  17. Sur S, Steele R, Shi X, Ray RB. miRNA-29b inhibits prostate tumor growth and induces apoptosis by increasing bim expression. Cells. 2019;8(11):1455.

  18. Hale V, Hale GA, Brown PA, Amankwah EK. A review of DNA methylation and microRNA expression in recurrent pediatric acute leukemia. Oncology. 2017;92(2):61-7.

  19. Zheng Y, Li L, Gao Q, Niu B, Wang H. Solanine inhibits proliferation and promotes apoptosis of the human leukemia cells by targeting the miR-16/Bcl-2 axis. J BUON. 2020;25(3):1614-8.

  20. Qiu J, Zhu J, Zhang R, Liang W, Ma W, Zhang Q, Huang Z, Ding F, Sun H. miR-125b-5p targeting TRAF6 relieves skeletal muscle atrophy induced by fasting or denervation. Ann Transl Med. 2019;7(18):456.

  21. Hui L, Zhang J, Guo X. miR-125b-5p suppressed the glycolysis of laryngeal squamous cell carcinoma by down-regulating hexokinase-2. Biomed Pharmacother. 2018;103:1194-201.

  22. Ramsey HE, Fischer MA. A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia. Cancer Discov. 2018;8(12):1566-81.

  23. Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, Chanrion M, Kelly GL, Gong JN, Moujalled DM, Bruno A, Csekei M, Paczal A, Szabo ZB, Sipos S, Radics G, Proszenyak A, Balint B, Ondi L, Blasko G, Robertson A, Surgenor A, Dokurno P, Chen I, Matassova N, Smith J, Pedder C, Graham C, Studeny A, Lysiak-Auvity G, Girard AM, Grave F, Segal D, Riffkin CD, Pomilio G, Galbraith LC, Aubrey BJ, Brennan MS, Herold MJ, Chang C, Guasconi G, Cauquil N, Melchiore F, Guigal-Stephan N, Lockhart B, Colland F, Hickman JA, Roberts AW, Huang DC, Wei AH, Strasser A, Lessene G, Geneste O. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016;538(7626):477-82.

  24. Dai YJ, He SY, Hu F, Li XP, Zhang JM, Chen SL, Zhang WN, Sun HM, Wang DW. Bone marrow infiltrated natural killer cells predicted the anti-leukemia activity of MCL1 or BCL2 inhibitors in acute myeloid leukemia. Mol Cancer. 2021;20(1):8.

  25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001;25(4):402-8.

  26. Morelli E, Leone E, Cantafio ME, Di Martino MT, Amodio N, Biamonte L, Gulla A, Foresta U, Pitari MR, Botta C, Rossi M, Neri A, Munshi NC, Anderson KC, Tagliaferri P, Tassone P. Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. Leukemia. 2015;29(11):2173-83.

  27. Xiong J, Wang H, Mu F, Liu Z, Bao Y, Sun Y. miR-125b-5p inhibitor might protect against sevoflurane-induced cognitive impairments by targeting LIMK1. Curr Neurovasc Res. 2019;16(4):382-91.

  28. Jurikova M, Danihel E, Polak S, Varga I. Ki67, PCNA, and MCM proteins: Markers of proliferation in the diagnosis of breast cancer. Acta Histochem. 2016;118(5):544-52.

  29. Lu EM, Ratnayake J. Assessment of proliferating cell nuclear antigen (PCNA) expression at the invading front of oral squamous cell carcinoma. BMC Oral Health. 2019;19(1):233.

  30. Kaplan JA. Leukemia in children. Pediatr Rev. 2019;40(7):319-31.

  31. Cao L, Wang N, Pan J, Hu S, Zhao W, He H, Wang Y, Gu G, Chai Y. Clinical significance of microRNA-34b expression in pediatric acute leukemia. Mol Med Rep. 2016;13(3):2777-84.

  32. Tang R, Li J, Yue M, Liu Z, Feng S, Tang S, Wang T. A correlation analysis of miRNA-34a and its predicted target genes in leukemia. Mol Med Rep. 2014;9(4):1283-8.

  33. Wei AH, Roberts AW, Spencer A, Rosenberg AS, Siegel D, Walter RB, Caenepeel S, Hughes P, McIver Z, Mezzi K, Morrow PK, Stein A. Targeting MCL1 in hematologic malignancies: Rationale and progress. Blood Rev. 2020;44:100672.

  34. Tron AE, Belmonte MA, Adam A, Aquila BM, Boise LH, Chiarparin E, Cidado J, Embrey KJ, Gangl E, Gibbons FD, Gregory GP, Hargreaves D, Hendricks JA, Johannes JW, Johnstone RW, Kazmirski SL, Kettle JG, Lamb ML, Matulis SM, Nooka AK, Packer MJ, Peng B, Rawlins PB, Robbins DW, Schuller AG, Su N, Yang W, Ye Q, Zheng X, Secrist JP, Clark EA, Wilson DM, Fawell SE, Hird AW. Discovery of MCLl-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun. 2018;9(1):5341.

  35. Klumper T, Bruckmueller H, Diewock T, Kaehler M, Haenisch S, Pott C, Bruhn O, Cascorbi I. Expression differences of miR-142-5p between treatment-naive chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance. Exp Hematol Oncol. 2020;9:26.

  36. Li C, Zhang Y, Zhao W, Cui S, Song Y. miR-153-3p regulates progression of ovarian carcinoma in vitro and in vivo by targeting MCL1 gene. J Cell Biochem. 2019;120(11):19147-58.

  37. Zhou C, Li G, Zhou J, Han N, Liu Z, Yin J. miR-107 activates ATR/Chk1 pathway and suppress cervical cancer invasion by targeting MCL1. PLoS One. 2014;9(11):e111860.

  38. Li Y, Wang Y, Fan H, Zhang Z, Li N. miR-125b-5p inhibits breast cancer cell proliferation, migration and invasion by targeting KIAA1522. Biochem Biophys Res Commun. 2018;504(1):277-82.

  39. Yang D, Zhan M, Chen T, Chen W, Zhang Y, Xu S, Yan J, Huang Q, Wang J. miR-125b-5p enhances chemotherapy sensitivity to cisplatin by down-regulating Bcl2 in gall-bladder cancer. Sci Rep. 2017;7:43109.

  40. Shaham L, Binder V, Gefen N, Borkhardt A, Izraeli S. miR-125 in normal and malignant hematopoiesis. Leukemia. 2012;26(9):2011-8.

  41. El-Khazragy N, Elshimy AA, Hassan SS, Matbouly S, Safwat G, Zannoun M, Riad RA. Dysregulation of miR-125b predicts poor response to therapy in pediatric acute lymphoblastic leukemia. J Cell Biochem. 2019;120(5):7428-38.

Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen Preise und Aborichtlinien Begell House Kontakt Language English 中文 Русский Português German French Spain